If you’re searching “short cervix pregnancy,” the key answer is that vaginal progesterone is generally recommended for an asymptomatic pregnancy with one baby when a transvaginal ultrasound finds a cervix of 25 mm (about 1 inch) or less in mid-pregnancy. It can reduce the chance of preterm birth, but it cannot guarantee that birth will happen at term. Your previous pregnancy history and how far along you are also matter.
Short Cervix Pregnancy: What The Measurement Means
A short cervix is usually defined as 25 mm or less, measured by transvaginal ultrasound. The measurement is commonly taken around the detailed anatomy scan, typically between 18 and 22 weeks. Transvaginal ultrasound is preferred because it gives a more reliable cervical-length measurement than an abdominal scan.
The shorter the cervix, the greater the risk of spontaneous preterm birth, but a measurement is a risk marker—not a prediction that labour will start. The treatment recommendations discussed here concern people who have no symptoms and are carrying a singleton pregnancy. Twin or other multiple pregnancies, and situations involving symptoms or cervical dilation, need a different clinical assessment.
How Strong Is The Case For Progesterone?
Evidence from randomized trials supports vaginal progesterone for reducing preterm-birth risk when a singleton pregnancy has a short cervix. An individual-patient-data meta-analysis led by Romero combined five trials. For pregnancies with a cervical length of 25 mm or less, birth before 33 weeks occurred in 14% of those given progesterone and 22% of those given placebo. The analysis also found lower rates of some serious newborn outcomes. Most participants had no previous preterm birth and a cervical length between 10 and 20 mm, so the results are especially relevant to that group.
The trials used vaginal gel or capsules, with daily doses ranging from 90 to 200 mg; most participants received 200 mg. Treatment generally began between 18 and 25 weeks and continued to 34–36 weeks. Those study schedules help explain why timing matters, but they are not a personal prescription. A 2025 review by Moti Gulersen, Vincenzo Berghella and Eran Bornstein describes vaginal progesterone as an evidence-based option supported by several professional organizations, including SMFM, ACOG, NICE and WHO.
Why Thresholds And Guidelines Differ
Organizations do not always frame the treatment threshold in exactly the same way. In the U.S., SMFM recommends vaginal progesterone when the cervix measures 20 mm or less before 24 weeks; at 21–25 mm, it recommends discussing the option and making a shared decision. NICE guidance in the UK offers progesterone when a cervix of 25 mm or less is identified between 16 and 24 weeks. Both approaches focus on a short cervix identified before 24 weeks; the difference is how clearly treatment is recommended in the 21–25 mm range.
If your result falls in that range, ask which guideline your maternity team follows and how your other risk factors affect the decision. A prior spontaneous preterm birth can change the plan, and some people at higher risk have cervical-length monitoring considered earlier in pregnancy.
How A Previous Preterm Birth Changes The Choice
If you have had a spontaneous preterm birth and now have a short cervix, cerclage—a stitch placed around the cervix—may be considered alongside progesterone. A 2018 indirect comparison meta-analysis by Agustin Conde-Agudelo, Roberto Romero and colleagues found no statistically significant difference between the treatments for people with a singleton pregnancy, a previous spontaneous preterm birth and a short mid-pregnancy cervix. Because it compared separate sets of trials rather than directly randomizing participants between the two treatments, it cannot prove that the options are identical for every patient. The decision can take account of your history, the procedure’s risks and your preferences.
For someone with no previous spontaneous preterm birth, a stitch is not automatically added to progesterone. In a randomized trial of 90 such participants with a cervix of 25 mm or less before 24 weeks, adding cerclage did not significantly reduce the main outcome of birth before 35 weeks compared with progesterone alone. Participants who had both treatments did have a longer interval to delivery and later gestational age at birth. The small trial leaves uncertainty about who, if anyone, benefits from adding a stitch in this group.
What To Ask Your Maternity Team
Confirm the exact cervical length, how it was measured and how many weeks pregnant you were at the scan. Ask whether progesterone is recommended under your local guidance, when treatment would start and how long it would continue. If you have a previous preterm birth, ask whether cerclage is relevant to your circumstances. Contact your maternity team promptly if you develop concerning symptoms such as contractions, bleeding or fluid leakage; a screening result alone cannot assess those symptoms.
These treatment findings do not apply to every pregnancy or prevent every early birth. Your clinician can interpret the scan alongside your pregnancy history and current symptoms.